|
|
|
|
| LEADER |
01000naa a22002652 4500 |
| 001 |
NLM362392641 |
| 003 |
DE-627 |
| 005 |
20231226091138.0 |
| 007 |
cr uuu---uuuuu |
| 008 |
231226s2023 xx |||||o 00| ||eng c |
| 024 |
7 |
|
|a 10.1016/j.clim.2023.109782
|2 doi
|
| 028 |
5 |
2 |
|a pubmed24n1207.xml
|
| 035 |
|
|
|a (DE-627)NLM362392641
|
| 035 |
|
|
|a (NLM)37742791
|
| 035 |
|
|
|a (PII)S1521-6616(23)00545-4
|
| 040 |
|
|
|a DE-627
|b ger
|c DE-627
|e rakwb
|
| 041 |
|
|
|a eng
|
| 100 |
1 |
|
|a Hou, Yi-Bo
|e verfasserin
|4 aut
|
| 245 |
1 |
0 |
|a Intravenous immunoglobulin in kidney transplantation
|b Mechanisms of action, clinical applications, adverse effects, and hyperimmune globulin
|
| 264 |
|
1 |
|c 2023
|
| 336 |
|
|
|a Text
|b txt
|2 rdacontent
|
| 337 |
|
|
|a ƒaComputermedien
|b c
|2 rdamedia
|
| 338 |
|
|
|a ƒa Online-Ressource
|b cr
|2 rdacarrier
|
| 500 |
|
|
|a Date Completed 06.11.2023
|
| 500 |
|
|
|a Date Revised 06.11.2023
|
| 500 |
|
|
|a published: Print-Electronic
|
| 500 |
|
|
|a Citation Status MEDLINE
|
| 520 |
|
|
|a Copyright © 2023 Elsevier Inc. All rights reserved.
|
| 520 |
|
|
|a Intravenous immunoglobulin (IVIG) has been developed for over 40 years. The mechanisms of action of IVIG are complex and diverse, and there may be multiple mechanisms that combine to influence it. IVIG has been used in kidney transplantation for desensitization, treatment of antibody-mediated rejection, and ABO-incompatible transplantation. and treatment or prevention of some infectious diseases. Hyperimmune globulins such as cytomegalovirus hyperimmune globulin (CMV-IG) and hepatitis B hyperimmune globulin (HBIG) have also been used to protect against cytomegalovirus and hepatitis B virus, respectively. However, IVIG is also associated with some rare but serious adverse effects and some application risks, and clinicians need to weigh the pros and cons and develop individualized treatment programs to benefit more patients. This review will provide an overview of the multiple mechanisms of action, clinical applications, adverse effects, and prophylactic measures of IVIG, and hyperimmune globulin will also be introduced in it
|
| 650 |
|
4 |
|a Journal Article
|
| 650 |
|
4 |
|a Review
|
| 650 |
|
4 |
|a Adverse effect
|
| 650 |
|
4 |
|a Hyperimmune globulin
|
| 650 |
|
4 |
|a Intravenous immunoglobulin
|
| 650 |
|
4 |
|a Kidney transplantation
|
| 650 |
|
4 |
|a Mechanism of action
|
| 650 |
|
7 |
|a Immunoglobulins, Intravenous
|2 NLM
|
| 700 |
1 |
|
|a Chang, Sheng
|e verfasserin
|4 aut
|
| 700 |
1 |
|
|a Chen, Song
|e verfasserin
|4 aut
|
| 700 |
1 |
|
|a Zhang, Wei-Jie
|e verfasserin
|4 aut
|
| 773 |
0 |
8 |
|i Enthalten in
|t Clinical immunology (Orlando, Fla.)
|d 1999
|g 256(2023) vom: 01. Nov., Seite 109782
|w (DE-627)NLM098196855
|x 1521-7035
|7 nnns
|
| 773 |
1 |
8 |
|g volume:256
|g year:2023
|g day:01
|g month:11
|g pages:109782
|
| 856 |
4 |
0 |
|u http://dx.doi.org/10.1016/j.clim.2023.109782
|3 Volltext
|
| 912 |
|
|
|a GBV_USEFLAG_A
|
| 912 |
|
|
|a SYSFLAG_A
|
| 912 |
|
|
|a GBV_NLM
|
| 912 |
|
|
|a GBV_ILN_11
|
| 912 |
|
|
|a GBV_ILN_24
|
| 912 |
|
|
|a GBV_ILN_350
|
| 951 |
|
|
|a AR
|
| 952 |
|
|
|d 256
|j 2023
|b 01
|c 11
|h 109782
|